In the previous post, GLP-1 agonists’ analysis revealed an extraordinary increase of 327% in spending over the years. This enormous increase makes us wonder about the trends of other anti-diabetics. In this post, we will explore the contribution of another drug class named SGLT2 Inhibitors to Medicare Part D spending.
(more…)Tag: Jardiance
-
Changing Trends in Medicare Part D Spending (2019–2023)
Medicare Part D aims to provide financial assistance to people, enabling them to buy prescribed drugs at reduced cost. It is available to people who are already part of the Medicare program. This drug coverage program effectively reduces the financial burden on the public.
The following post is an analysis of publicly available Medicare Part D drug spending data for the years 2019-2023. It may seem outdated, as we are currently in 2026. However, data collection and recordkeeping usually take years to complete. So, the data used for analysis is the latest available record published by the Centers for Medicare and Medicaid Services(CMS) on its official website.
(more…)